1438-PGE2-Driven Dendritic Cell Dysfunction in Breast Cancer

This research article explores how prostaglandin E2 (PGE2) causes immune evasion in breast cancer patients with skin involvement. By analyzing patient tissues and mouse models, the study identifies that high levels of this metabolite impair the activation of dendritic cells, preventing them from effectively priming T lymphocytes to attack the tumor. Clinical data indicates that low dendritic cell activity and high PGE2 levels are linked to worse survival outcomes and poor treatment responses. The authors demonstrate that blocking PGE2 or its synthesis via inhibitors like celecoxib can successfully restore immune function and reduce skin lesions. These findings suggest that targeting PGE2 metabolism offers a promising new therapeutic strategy for managing aggressive skin-related cancer progression.References:Wang J, Zhong X, Liu X, et al. Prostaglandin E2 induces dendritic cell dysfunction in skin involvement of breast cancer[J]. Cell Death & Disease, 2026, 17(1): 260.前往小宇宙评论区与主播互动